Poland· PL-100410723
Onpattro
A patisiran product containing patisiranum natricum, registered in Poland by Alnylam Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Patisiran is registered in 12 of 19 countries.
Countries holding a registration under ATC N07XX12 (patisiran), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Patisiran · ATC N07XX12
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Patisiranum natricum
- Manufacturer
- Alnylam Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- N07XX12
- ATC class
- Patisiran
- Defined daily dose
- 1 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin08719326368597
- gtin08720165814237
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Patisiran in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandOnpattroAlnylam Netherlands B.V.
- IcelandOnpattroAlnylam Netherlands B.V.
- SwedenOnpattro 2 mg/ml Koncentrat till infusionsvätska, lösningAlnylam Netherlands B.V.
- CanadaONPATTROALNYLAM NETHERLANDS B.V.
- SwitzerlandOnpattro 2 mg/ml, Konzentrat zur Herstellung einer InfusionslösungAlnylam Switzerland GmbH
- SpainONPATTRO 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONAlnylam Netherlands B.V.
- FranceONPATTRO 2 mg/mL, solution à diluer pour perfusionALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomOnpattro 10mg/5ml concentrate for solution for infusion vialsAlnylam UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Onpattro
- Liechtenstein · Onpattro
- Norway · Onpattro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1ba718da-15e2-4561-b2bd-bba7c8c03f4e GET /v1/drugs/1ba718da-15e2-4561-b2bd-bba7c8c03f4e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "2 mg/ml",
"packaging": "Rpz ¦ EU/1/18/1320/001 ¦ 129637\n1 fiol. \n¦ UR/Z/4b/023/21 - 08719326368597 ¦ UR/Z/4b/109/22 - 08719326368597 ¦ UR/Z/4b/185/22 - 08720165814237",
"substance": "Patisiranum natricum 2 mg/ml",
"common_name": "Patisiranum natricum",
"pl_product_id": "100410723",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about patisiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.